These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 22652058

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation.
    Nakayama K, Sakurai T, Katsu H.
    Brain Res Bull; 2004 Apr 30; 63(3):237-41. PubMed ID: 15145142
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Noradrenergic terminals are the primary source of α2-adrenoceptor mediated dopamine release in the medial prefrontal cortex.
    Devoto P, Flore G, Saba P, Scheggi S, Mulas G, Gambarana C, Spiga S, Gessa GL.
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar 02; 90():97-103. PubMed ID: 30472147
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia.
    Masana M, Bortolozzi A, Artigas F.
    Int J Neuropsychopharmacol; 2011 Feb 02; 14(1):53-68. PubMed ID: 20701825
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus.
    Li Z, Huang M, Prus AJ, Dai J, Meltzer HY.
    Brain Res; 2007 Feb 23; 1134(1):70-8. PubMed ID: 17207474
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Hippocampal and prefrontal dopamine D1/5 receptor involvement in the memory-enhancing effect of reboxetine.
    De Bundel D, Femenía T, DuPont CM, Konradsson-Geuken Å, Feltmann K, Schilström B, Lindskog M.
    Int J Neuropsychopharmacol; 2013 Oct 23; 16(9):2041-51. PubMed ID: 23672849
    [Abstract] [Full Text] [Related]

  • 20. Effects of acute and chronic reboxetine treatment on stress-induced monoamine efflux in the rat frontal cortex.
    Page ME, Lucki I.
    Neuropsychopharmacology; 2002 Aug 23; 27(2):237-47. PubMed ID: 12093597
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.